Although intended for the lungs, many drugs are not given via the airway because drug properties make it too difficult to formulate for direct to lung delivery. Given systemically, these drugs often produce unwanted and potentially life-threatening side effects. To get around this, companies have tried to use microcapsules, carriers, and other agents to try to dose drugs direct to the lungs, but these other delivery agents often produce their own problems. Using its proprietary technology, TFF can generate dry powder inhaler versions of these drugs using nothing but the drug itself and approved lung friendly ingredients. This means that drugs of all types â small molecules, biologics, even combinations â can be dosed direct to the lungs with few, if any, side effects. Source
No articles found.
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focu...
Strongbridge Biopharma is a global commercial-s...
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused ...
DiaMedica Therapeutics Inc. is a clinical stage...
Caresafe has developed a self-sanitizing surface coating system that creates conti...
Caresafe has developed a self-sanitizing surfac...
Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to address...
Foamix Pharmaceuticals is a specialty pharmaceu...
Join the National Investor Network and get the latest information with your interests in mind.